fi eld changes. Pretechnology licensing federal dollars all but disappear, and inventions / innovations rely predominantly on private funding to support the full path from bench to bedside.
Biomedical and phar maceutical development is quite risky, and the need to prove safety and efficacy through the FDA ' s NDA / PMA / BLA process is onerous and expensive. Additionally, everincreasing expenditures for R&D programs have produced diminishing returns [2] . Faced with this reality, large biomedical and pharmaceutical companies have decreased their internal product Most biomedical basic research in the United States takes place at academic / medical universities and research institutes and is funded by federal grants. Basic research is awarded billions of federal dollars every year, enabling new discoveries and greater understanding of the fundamental science that makes new innovations and therapies possible [1] . However, when basic research yields an invention of practical use and the research evolves from basic to applied, 1 the playing R&D expenditures and have sought to offl oad new product development risk onto capital markets by seeking more developed and proven -therefore, less risky -new-product candidates through licensing or development agreements with smaller investor -fi nanced companies.
Similarly, these smaller investor -backed companies also seek more developed newproduct pipeline candidates, rather than early -development stage projects. New product or therapeutic candidates must be at least somewhat developed before even smaller investor -backed companies will consider licensing these assets from universities and institutes.
In this environment, established companies as well as startups demand increasingly sophisticated and compelling
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The two valleys of death
The relatively few scientifi c advances for which suffi ciently novel tools are developed by researcher -inventors at institutions that do meet the basic criteria for out -licensing (e.g., drugs, biologics, clinical diagnostics, and medical devices) are soon confronted with the fi rst of two " valleys of death " ( Fig. 1 ). The fi rst valley of death (Valley 1) refers to the time period between initial discovery of the invention and outlicensing. Many inventions that make it past the discovery hurdle in the development pathway ultimately " die " in Valley 1 for the same reason relatively few scientifi c advances make it off the lab bench -lack of resources. In this case, however, while the researcher had access to suffi cient resources to generate a viable product candidate (and assuming an otherwise successful product), she / he lacked access to the skilled personnel, funds, facilities, and / or quality biomaterials necessary to perform critical preclinical in vivo investigative studies. Without reliable proof -of -concept data that products and therapies under consideration can survive the product and clinical development process through to marketing before they will consider entering into definitive licensing or codevelopment agreements.
The reality of " bench to bedside "
In the journey from scientif ic conceptualization to the actual application of a medical breakthrough, or from " bench to bedside, " many scientifi c advances never make it off the bench. This is primarily because there are essentially no federal funds available to universities and institutes prior to licensing to support the discovery and development of tools physicians can prescribe to patients, which take advantage of the revelations of basic research. Arguably, the individuals best positioned to discover new therapeutics or diagnostics to exploit a newly discovered " drug " target or biomarker -and by doing so, to more fully validate the new discoveryare the researchers who made the discovery and identifi ed its importance in the disease pathway. There are effectively no federal funds available for this purpose.
Scarce resources force many institutional researchers interested in developing therapeutics to seek less -than -ideal methods. For example, some seek to intervene in a newly discovered disease pathway by using known drugs, a practice called drug " repurposing " [3] . While this practice eliminates the immediate need for drug discovery, it also eliminates the possibility of attaining the " composition of matter " -type patent claims that drug and biotechnology companies strongly prefer over relatively weaker process -type patents. A strong defensible intellectual property position and the de facto monopoly position it enables are important to investorbacked companies as " insurance " that only their company will benefi t from the substantial investment that must be made to commercialize a biomedical product.
Select institutions such as the California Institute for Regenerative Medicine, MIT ' s
FIG. 1. Valleys of death.
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been " de -risked " suffi ciently for investors to conclude probability of success is reasonable.
For any given product opportunity, the realizable market size " is what it is. " While differing levels of marketing expenditure can affect speed and depth of market penetration, by the time a biomedical product approaches the development phase implied by Valley 1, the product characteristics responsible for determining realizable market size (the disease addressed, whether it is a drug, cell therapy, therapeutic protein, etc.) are " hard -wired " into the product and are largely unchangeable. It is quite diffi cult, if not impossible, to pivot such a biomedical product in response to market feedback or to bring the product back in line with the desired target product profi le.
In contrast, the second determinant of a given product ' s expected value, the riskiness of the endeavor, has components that are more amenable to change after creation of the product. Assuming that the fundamental science of the product is sound, most of the residual risk of a therapeutic stems from execution risk. " Execution risk " is the decision -making of the therapeutic ' s inventor and the company ' s management team responsible for product development. In other words, the decisions made pursuant to putting the scientific advance into the form of a therapeutic -the clinical tool physicians will prescribe to their patients, thus the vehicle used to translate the scientifi c advance into a medical breakthroughare the largest source of non -productrelated investment risk in any biomedical business opportunity.
Bridging the valleys of death: the role of blood and tissue banks
Blood and tissue banks can help in the translation of biomedical advances into clinically useful tools and their delivery to the bedside. Independent, nonprofi t blood
FIG. 2. Opportunity evaluation model.
Realizable Market Size × Probability of Success of ROI = Expected Value of Investment investment of some magnitude. While the U.S. Small Business Innovation Research / Small Business Technology Transfer [101] program provides important funding to support product -related applied / translational efforts focused on agency -defined areas of interest, the program is intended for small for -profi t businesses (e.g., the primary investigator must be employed by the small business). While some of the funds may be used at institutions (as subcontractors), the applicant must be a small business, not an institution and generally not prior to institutional technology transfer outlicensing. Thus, most funding for discovery and development of novel biomedical tools comes from private investment and / or is driven by privatesector companies.
Holders of private investment funds, whether for -profi t concerns or not -forprofi t organizations, expect to receive some level of positive return on investment. Since biomedical investments are generally quite risky, it is not surprising that managers of these funds typically require a substantial expected return to compensate for the fi nancial risks taken. It is this notion of fi nancial / business / investment risk that is the root cause of the two valleys of death ( Fig. 2 ) .
Expected value and risk
Since the expected value of any fi nancial investment is equal to the realizable market size multiplied by the probability of success of achieving fi nancial return, the drivers of investment decision -making are (1) achievable market size given the planned investment and (2) risks inherent to the endeavor. Accordingly, biomedical investors are most interested in (1) companies with pipeline products with a total realizable market potential of suffi cient size, and (2) For investors, companies with cell -based therapies in their pipelines may greatly diminish perceived risk by partnering with blood and tissue banks, and especially advanced blood and tissue banks for the recovery, safety testing, processing, manufacturing, quality assurance, distribution, and perhaps eventually administration of cell -based therapies.
Profi le of an advanced blood and tissue bank: BioBridge Global
Headquartered in San Antonio, Texas, BioBridge Global is the 501(c)(3) not -forprofit parent organization to three operating subsidiaries and one supporting foundation structured similarly as not -forprofi t organizations. From its beginning in 1974 as South Texas Regional Blood Bank to the establishment in 2007 of our blood and tissue safety testing group QualTex Laboratories to the 2010 founding of our regenerative medicinefocused group known as GenCure, the organization that has grown into BioBridge Global has a history of missiondriven innovation.
" Connecting donors with patients, needs with solutions, and opportunities with growth " is BioBridge Global ' s mission. BioBridge seeks to save and enhance lives around the world by building relationships with like -minded nonprofi t and for -profi t organizations and by leveraging the complementary resources and capabilities of the three operating subsidiaries, as well for predicting cell potency, and closedsystem fi ll and fi nish become available, researchers can partner with more advanced blood and tissue banks for IND -enabling cell -based therapeutic products as early as the preclinical phase ( Table 1 ).
Biotechnology and cell -based therapeutics companies approaching Valley 2 also can benefit from blood and tissue banks ' increased capabilities. While advanced cell -based therapeutics such as Dendreon ' s Provenge are relatively new, blood and tissue banks have been operating under cGMP and / or GTP controls for decades. Blood and tissue banks are accustomed to operating under the strictest qualitycontrol standards because red blood cells, plasma, platelets, cord blood, and implantable tissues must be safe and effective every time. Donated and processed human cell and tissue products are biotherapeutics because the cell -based products of blood and tissue banks (red cells, whole blood, platelets, cord blood, and peripheral blood stem cells) confer therapeutic benefi t via the use of living cells.
Blood and tissue banks wishing to engage in interstate distribution of their blood products must seek licensure of their products through the FDA ' s biologics and tissue banks have the freedom, charters, and mission to engage in activities that are out of scope for most universities and not fi nancially attractive enough for most private for -profit companies to undertake.
Blood and tissue banks have access to human biomaterials and related skills that researchers and biomedical companies can leverage to attenuate the perceived risk of their pipeline biomedical products. Also, many are members of blood and tissue bank alliance networks, which contract with biomedical companies for services on behalf of their members.
For example, with regard to Valley 1, researchers can reduce perceived risk of novel cell -and tissue -based technologies by sourcing the human biomaterials used in their research from accredited blood and tissue banks. Because accredited blood and tissue banks follow strict standard operating procedures and comply with all relevant accrediting agency and regulatory agency requirements, researchers can be confident that the human biomaterials used to conduct research are of the highest quality. Some blood and tissue banks also have considerable experience with cell processing, component separation, cell banking, biomarker -based cell quantifi cation, custom antigen assays, and other core competencies.
Some blood and tissue banks have active applied research laboratories and are especially receptive to partnering with researchers with technologies showing promise to address long -standing areas of need within the industry. Some blood and tissue banks, especially ones that are a part of a parent organization with several divisions encompassing different but complementary capabilities, offer advanced services, possess significant biomedical processing facilities, have broad core competencies and can be especially helpful at bridging the valleys of death. As technologies enabling costeffective manufacturing of cell -based therapeutics, rapid and reliable methods For investors, companies with cell -based therapies in their pipelines may greatly diminish perceived risk by partnering with blood and tissue banks. 
